Loading clinical trials...
Loading clinical trials...
A Phase 1, Open-Label, Multicenter Study of ADA-011 as Monotherapy and in Combination With a Checkpoint Inhibitor for Subjects With Advanced Solid Tumors
Conditions
Interventions
ADA-011
PD(L)-1 inhibitor
Locations
5
United States
HonorHealth
Scottsdale, Arizona, United States
Florida Cancer Specialists
Orlando, Florida, United States
Duke University
Durham, North Carolina, United States
The Christ Hospital
Cincinnati, Ohio, United States
Oregon Health & Science University
Portland, Oregon, United States
Start Date
November 15, 2022
Primary Completion Date
October 30, 2024
Completion Date
October 30, 2024
Last Updated
January 28, 2025
NCT05223608
NCT06625775
NCT06051695
NCT06265727
NCT04665206
NCT05036226
Lead Sponsor
Adanate, Inc
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions